Veraxa Biotech AG (VRXA)

NASDAQ: VRXA · Real-Time Price · USD

1.135

+0.005 (0.44%)

Oct 30, 2026, 10:47 AM EDT - Market open

Veraxa Biotech AG Financials Overview

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	0.02	0.02	-	-
Revenue Growth	-	-	-	-
Gross Profit	0.02	0.02	-	-
Operating Income	-66.22	-66.22	-28.92	-16.66
Net Income	-66.61	-66.61	-28.13	-16.54
Earnings Per Share	-4.60	-4.60	-2.00	-1.21
EPS Growth	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	1.61	1.61	5.36	11.35
Total Debt	1.14	1.14	0.86	-
Net Cash (Debt)	0.47	0.47	4.5	11.35
Net Cash Growth	-	-89.48%	-60.38%	-
Net Cash Per Share	0.03	0.03	0.32	0.83

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-9.9	-9.9	-7.72	-7.27
Capital Expenditures	-0.44	-0.44	-0.12	-0.23
Free Cash Flow	-10.34	-10.34	-7.84	-7.5
Free Cash Flow Growth	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Gross Margin	66.00%	66.00%	-	-
Operating Margin	-282662.75%	-282662.75%	-	-
Pretax Margin	-286035.14%	-286035.14%	-	-
Profit Margin	-284359.22%	-284359.22%	-	-
FCF Margin	-44136.89%	-44136.89%	-	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Oct '26 Oct 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
PS Ratio	5408.75	11422.01	-	-